<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25749632</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>10</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1469-493X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2015</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Mar</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Cochrane database of systematic reviews</Title>
          <ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Perphenazine for schizophrenia.</ArticleTitle>
        <Pagination>
          <StartPage>CD003443</StartPage>
          <MedlinePgn>CD003443</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">CD003443</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD003443.pub3</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Perphenazine is an old phenothiazine antipsychotic with a potency similar to haloperidol. It has been used for many years and is popular in the northern European countries and Japan.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To examine the clinical effects and safety of perphenazine for those with schizophrenia and schizophrenia-like psychoses.</AbstractText>
          <AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">We updated our original search using the Cochrane Schizophrenia Group's register (September 2013), references of all included studies and contacted pharmaceutical companies and authors of included studies in order to identify further trials.</AbstractText>
          <AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">We included all randomised controlled trials that compared perphenazine with other treatments for people with schizophrenia and/or schizophrenia-like psychoses. We excluded trials of depot formulations of perphenazine.</AbstractText>
          <AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two review authors independently inspected citations and, where possible, abstracts. We ordered papers, inspected and quality assessed them. We extracted data, again working independently. If loss to follow-up was greater than 50% we considered results as 'prone to bias'. For dichotomous data, we calculated risk ratios (RR) and for continuous data we calculated mean differences (MD), both with the 95% confidence intervals (CI). We assessed quality of data using the GRADE (Grading of Recommendations Assessment, Development and Evaluationtool) and assessed risk of bias for included studies.</AbstractText>
          <AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Thirty-one studies fulfilled the inclusion criteria, with a total of 4662 participants (of which 4522 were receiving the drugs relevant to our comparison) and presented data that could be used for at least one comparison. The trial centres were located in Europe (especially Scandinavia), Japan and Northern America.When comparing perphenazine with placebo, for our primary outcome of clinical response, results favoured perphenazine with significantly more people receiving placebo rated as either 'no better or deterioration' for global state than people receiving perphenazine (1 RCT, n = 61 RR 0.32 CI 0.13 to 0.78, very low quality evidence). More people receiving placebo relapsed, although not a statistically significant number (1 RCT, n = 48, RR 0.14 CI 0.02 to 1.07, very low quality evidence). Death was not reported in the perphenazine versus placebo comparison. Experiences of dystonia were equivocal between groups (1 RCT, n = 48, RR 1.00 CI 0.07 to 15.08, very low quality evidence); other outcomes not reported in this comparison include serious adverse events, economic outcomes, and service use and hospitalisation.For the comparison of perphenazine versus any other antipsychotic drugs, no real differences in effect between the drugs were found. There was no significant difference between groups for those considered 'no better or deterioration' (17 RCTs, n = 1879, RR 1.04 CI 0.91 to 1.17, very low quality evidence). For mental state outcome of 'no effect' of the study drug, there was again no significant difference between groups (4 RCTs, n = 383, RR 1.24 CI 0.61 to 2.52, very low quality evidence). Death was not reported in any of the included studies. There was no significant difference in rates of dystonia with perphenazine versus any other antipsychotic drugs (4 RCTs, n = 416, RR 1.36 CI 0.23 to 8.16, very low quality evidence), nor was there a significant difference between groups for serious adverse events (2 RCTs, n = 1760, RR 0.98 CI 0.68 to 1.41, very low quality evidence).</AbstractText>
          <AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">Although perphenazine has been used in randomised trials for more than 50 years, incomplete reporting and the variety of comparators used make it impossible to draw clear conclusions. All data for the main outcomes in this review were of very low quality evidence. At best we can say that perphenazine showed similar effects and adverse events as several of the other antipsychotic drugs. Since perphenazine is a relatively inexpensive and frequently used compound, further trials are justified to clarify the properties of this classical antipsychotic drug.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hartung</LastName>
            <ForeName>Benno</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Legal Medicine, University Hospital Düsseldorf, Moorenstr. 5, Düsseldorf, North Rhine Westphalia, Germany, 40225.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sampson</LastName>
            <ForeName>Stephanie</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leucht</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>10/4001/15</GrantID>
            <Acronym>DH_</Acronym>
            <Agency>Department of Health</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>03</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cochrane Database Syst Rev</MedlineTA>
        <NlmUniqueID>100909747</NlmUniqueID>
        <ISSNLinking>1361-6137</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FTA7XXY4EZ</RegistryNumber>
          <NameOfSubstance UI="D010546">Perphenazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="UpdateOf">
          <RefSource>Cochrane Database Syst Rev. 2005;(1):CD003443</RefSource>
          <PMID Version="1">15674907</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010546" MajorTopicYN="N">Perphenazine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Benno Hartung ‐ none known. 
Stephanie Sampson ‐ none known. 
Stefan Leucht ‐ S. Leucht has received lecture honoraria from EliLilly, Lundbeck, Pfizer, Janssen, Johnson and Johnson, BristolMyersSquibb, Lundbeck, Roche, SanofiAventis, ICON and Abbvie; honoraria for consulting from Roche, Janssen, Lundbeck, and EliLilly; for the preparation of educational material and publications from the Lundbeck Institute and Roche. EliLilly has provided medication for a clinical trial led by SL as principal investigator.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25749632</ArticleId>
        <ArticleId IdType="pmc">PMC7173727</ArticleId>
        <ArticleId IdType="doi">10.1002/14651858.CD003443.pub3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References to studies included in this review</Title>
        <ReferenceList>
          <Title>Amakusa 1973 {published data only}</Title>
          <Reference>
            <Citation>Amakusa T, 
Majima T. 
The comparison of therapeutic effects of FK‐880 (sulpiride) and perphenazine in schizophrenia by a double‐blind controlled study. 
Juntendo Igako 1973;19(2):239‐49.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bennett 1961 {published data only}</Title>
          <Reference>
            <Citation>Bennett JL, 
Kooi KA. 
Five phenothiazine derivates. evaluation and toxicity studies. 
Archives of General Psychiatry 1961;4:413‐8.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>CATIE 2005 {published data only}</Title>
          <Reference>
            <Citation>CATIE ‐ Schizophrenia Trial. 
National Institute of Mental Health (NIMH), NCT00014001 Study start: December 2000; Study completion: December 2004.
</Citation>
          </Reference>
          <Reference>
            <Citation>Addington D. 
Impact of second generation antipsychotic drugs and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. 
Proceedings of the 164th annual general meeting of the American Psychiatric Association; 2011 May 14‐18; Honolulu, Hawaii 2011. 
[CATIE]
</Citation>
          </Reference>
          <Reference>
            <Citation>Addington DE, 
Mohamed S, 
Rosenheck RA, 
Davis SM, 
Stroup TS, 
McEvoy JP, 
et al. 
Impact of second‐generation antipsychotic drugs and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. 
Journal of Clinical Psychiatry 2011; Vol. 72, issue 1:75‐80. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC5052810</ArticleId>
              <ArticleId IdType="pubmed">20868641</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Anon. 
Antipsychotic medications for schizophrenia on equal footing in improving patients' thinking skills. 
Science Update 2007:1. 
[ANON: 2007 h]
</Citation>
          </Reference>
          <Reference>
            <Citation>Ascher‐Svanum H, 
Nyhuis AW, 
Faries DE, 
Heiler L, 
Kinon BJ. 
Treatment discontinuation following randomization to open‐label olanzapine, risperidone or typical antipsychotic drugs during a one‐year treatment for schizophrenia. 
Clinical Schizophrenia &amp; Related Psychoses. United States, 2008; Vol. 2, issue 3:226‐34. 
[ASCHER‐SVANUM: 2008]
</Citation>
          </Reference>
          <Reference>
            <Citation>Bick P, 
Knoesen N, 
Castle D. 
Clinical implications of the CATIE schizophrenia trials: day‐to‐day management lessons for Australasian psychiatrists. 
Australasian Psychiatry 2007; Vol. 15, issue 6:465‐9. 
[CATIE: 2003]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17999256</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Essock SM, 
Covell NH, 
Davis SM, 
Stroup TS, 
Rosenheck RA, 
Lieberman JA. 
Effectiveness of switching antipsychotic medications. 
American Journal of Psychiatry 2006; Vol. 163, issue 12:2090‐5. 
[ESSOCK: 2006 b]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17151159</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Gutierrez‐Suela F. 
Selection of antipsychotic drugs in a psychiatric hospital based on the results of CATIE study. 
Farmacia Hospitalaria 2008; Vol. 32, issue 2:83‐90. 
[GUTIERREZ‐SUELA: 2008]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">18783707</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Haddad PM, 
Dursun S. 
Selecting antipsychotic drugs in schizophrenia: lessons from CATIE. 
Journal of Psychopharmacology (Oxford, England) 2006; Vol. 20, issue 3:332‐4. 
[CATIE: 2003]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">16574710</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Hermes E, 
Nasrallah H, 
Davis V, 
Meyer J, 
McEvoy J, 
Goff D, 
et al. 
The association between weight change and symptom reduction in the CATIE schizophrenia trial. 
Schizophrenia Research 2011; Vol. 128, issue 1‐3:166‐70. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC3789238</ArticleId>
              <ArticleId IdType="pubmed">21334853</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Hermes E, 
Rosenheck R. 
Choice of randomization to clozapine versus other second generation antipsychotic drugs in the CATIE schizophrenia trial. 
Journal of Psychopharmacology (Oxford, England) 2012; Vol. 26, issue 9:1194‐200. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC3789241</ArticleId>
              <ArticleId IdType="pubmed">22516668</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Hermes ED, 
Sokoloff D, 
Stroup TS, 
Rosenheck RA. 
Minimum clinically important difference in the positive and negative syndrome scale with data from the clinical antipsychotic trials of intervention effectiveness (CATIE). 
Journal of Clinical Psychiatry 2012; Vol. 73, issue 4:526‐32. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC3786588</ArticleId>
              <ArticleId IdType="pubmed">22579152</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Jin Y, 
Pollock BG, 
Coley K, 
Miller D, 
Marder SR, 
Florian J, 
et al. 
Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. 
Journal of Clinical Pharmacology 2010; Vol. 1, issue 1:73‐80. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC3648660</ArticleId>
              <ArticleId IdType="pubmed">19843655</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Keefe R. 
Neurocognitive efficacy in patients with chronic schizophrenia. 
European Neuropsychopharmacology 2006;16(Suppl 4):S577.
</Citation>
          </Reference>
          <Reference>
            <Citation>Keefe RSE, 
Bilder RM, 
Davis SM, 
Harvey PD, 
Palmer BW, 
Gold JM, 
et al. 
CATIE Investigators, 
Neurocognitive Working Group. 
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. 
ArchIves of General Psychiatry 2007;64(6):633‐47.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17548746</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Levine SZ, 
Rabinowitz J, 
Ascher‐Svanum H, 
Faries D, 
Lawson T. 
Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. 
Value in Health 2011; Vol. 7, issue 7:14. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">22000938</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Levine SZ, 
Rabinowitz J, 
Ascher‐Svanum H, 
Faries DE, 
Lawson AH. 
Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. 
Schizophrenia Research 2011; Vol. 133, issue 1‐3:42‐6. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">22000938</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Lieberman JA, 
Stroup TS, 
McEvoy JP, 
Swartz MA, 
Rosenheck RA, 
Perkins DO, 
et al. 
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. 
New England Journal of Medicine 2005;353(12):1209‐23.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">16172203</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Lin LA. 
Comparing antipsychotic treatments for schizophrenia: A health state approach. 
Dissertation Abstracts International: Section B: The Sciences and Engineering 2012; Vol. 73, issue 2‐B:863. 
[CATIE]
</Citation>
          </Reference>
          <Reference>
            <Citation>McEvoy JP, 
Lieberman JA, 
Stroup TS, 
Davis SM, 
Meltzer HY, 
Rosenheck RA, 
et al. 
CATIE Investigators. 
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. 
American Journal of Psychiatry 2006;163(4):600‐10. 
[DOI: 10.1176/appi.ajp.163.4.600]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1176/appi.ajp.163.4.600</ArticleId>
              <ArticleId IdType="pubmed">16585434</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Meyer JM, 
McEvoy JP, 
Davis VG, 
Goff DC, 
Nasrallah HA, 
Davis SM, 
et al. 
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. 
Biological Psychiatry 2009; Vol. 66, issue 11:1013‐22. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC3743723</ArticleId>
              <ArticleId IdType="pubmed">19640511</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Miller DD, 
Caroff SN, 
Davis SM, 
Rosenheck RA, 
McEvoy JP, 
Saltz BL, 
et al. 
Extrapyramidal side‐effects of antipsychotic drugs in a randomised trial. 
British Journal of Psychiatry 2008; Vol. 193, issue 4:279‐88. 
[CATIE: 2003]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2801816</ArticleId>
              <ArticleId IdType="pubmed">18827289</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Nasrallah HA. 
Metabolic findings from the CATIE trial and their relation to tolerability. 
CNS Spectrums 2006; Vol. 11, issue 7 Suppl 7:32‐9. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">16816798</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Olfson M, 
Ascher‐Svanum H, 
Faries DE, 
Marcus SC. 
Predicting psychiatric hospital admission among adults with schizophrenia. 
Psychiatric Services (Washington, D.C.) 2011; Vol. 62, issue 10:1138‐45. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">21969639</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Penn DL, 
Keefe RSE, 
Davis SM, 
Meyer PS, 
Perkins DO, 
Losardo D, 
et al. 
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. 
Schizophrenia Research 2009; Vol. 115, issue 1:17‐23. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2765056</ArticleId>
              <ArticleId IdType="pubmed">19766459</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Perlick DA, 
Rosenheck RA, 
Kaczynski R, 
Swartz MS, 
Canive JM, 
Lieberman JA. 
Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. 
Schizophrenia Research 2010; Vol. 116, issue 2‐3:118‐25. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">19864114</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Resnick SG, 
Rosenheck RA, 
Canive JM, 
Souza CD, 
Stroup TS, 
McEvoy J, 
et al. 
Employment outcomes in a randomized trial of second‐generation antipsychotic drugs and perphenazine in the treatment of individuals with schizophrenia. 
Journal of Behavioural Health Services and Research 2008;35(2):215‐25.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">18246429</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Rosenheck R, 
Swartz M, 
McEvoy J, 
Stroup TS, 
Davis S, 
Keefe RS, 
et al. 
Second‐generation antipsychotic drugs: Reviewing the cost‐effectiveness component of the CATIE trial. 
Expert Review of Pharmacoeconomics &amp; Outcomes Research 2007; Vol. 7, issue 2:103‐11. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">20528436</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Rosenheck RA, 
Davis VG, 
Davis SM, 
Stroup S, 
McEvoy J, 
Swartz M, 
et al. 
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. 
Schizophrenia Research 2009; Vol. 113, issue 1:12‐8. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC6474782</ArticleId>
              <ArticleId IdType="pubmed">19545976</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Rosenheck RA, 
Leslie DL, 
Sindelar J, 
Miller EA, 
Lin H, 
Stroup TS, 
et al. 
Cost‐effectiveness of second‐generation antipsychotic drugs and perphenazine in a randomized trial of treatment for chronic schizophrenia. 
American Journal of Psychiatry 2006;163(12):2080‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17151158</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Schulte PFJ, 
Haan L. 
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. 
Tijdschrift voor Psychiatrie 2006;48(3):243‐4.
</Citation>
          </Reference>
          <Reference>
            <Citation>Stroup S, 
Appelbaum P, 
Swartz M, 
Patel M, 
Davis S, 
Jeste D, 
et al. 
Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. 
Schizophrenia Research 2005; Vol. 80, issue 1:1‐8. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">16182516</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Stroup TS. 
Comparison of ziprasidone versus other atypical drugs in prospectively defined, unresponsive patients. 
Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25, Toronto, Canada. 2006.
</Citation>
          </Reference>
          <Reference>
            <Citation>Stroup TS, 
Leiberman JA, 
McEvoy JP, 
Swartz MS, 
Davis SM. 
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. 
American Journal of Psychiatry 2006;163:611‐22.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">16585435</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Stroup TS, 
Lieberman JA, 
McEvoy JP, 
Davis SM, 
Swartz MS, 
Keefe RSE, 
et al. 
Results of phase 3 of the CATIE schizophrenia trial. 
Schizophrenia Research 2009; Vol. 107, issue 1:1‐12. 
[CATIE: 2003]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2675163</ArticleId>
              <ArticleId IdType="pubmed">19027269</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Stroup TS, 
Lieberman JA, 
McEvoy JP, 
Swartz MS, 
Davis SM, 
Capuano GA, 
et al. 
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. 
American Journal of Psychiatry 2007;164(3):415‐27.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17329466</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Stroup TS, 
McEvoy JP, 
Swartz MS, 
Byerly MJ, 
Glick ID, 
Canive JM, 
et al. 
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developme. 
Schizophrenia Bulletin 2003;29(1):15‐31.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">12908658</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Swartz MS, 
Perkins DO, 
Stroup TS, 
Davis SM, 
Capuano G, 
Rosenheck RA, 
et al. 
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. 
American Journal of Psychiatry 2007;164(3):428‐36.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17329467</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Swartz MS, 
Stroup TS, 
McEvoy JP, 
Davis SM, 
Rosenheck RA, 
Keefe RS, 
et al. 
What CATIE found: results from the schizophrenia trial. 
Psychiatry Online May 2008;59(5):500‐06.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC5033643</ArticleId>
              <ArticleId IdType="pubmed">18451005</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Swartz MS, 
Wagner HR, 
Swanson JW, 
Stroup TS, 
McEvoy JP, 
Reimherr F, 
et al. 
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. 
Schizophrenia Research 2008;100(1‐3):39‐52.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">18191383</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Tsai HT, 
Caroff SN, 
Miller DD, 
McEvoy J, 
Lieberman JA, 
North KE, 
et al. 
A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. 
American Journal of Medical Genetics 2010; Vol. 153B, issue 1:336‐40. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC3894657</ArticleId>
              <ArticleId IdType="pubmed">19475583</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Wessels AM, 
Bies RR, 
Pollock BG, 
Schneider LS, 
Lieberman JA, 
Stroup S, 
et al. 
Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. 
Journal of Clinical Pharmacology 2011; Vol. 51, issue 11:1587‐91. 
[CATIE]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">21209243</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Chouinard 1975 {published data only}</Title>
          <Reference>
            <Citation>Chouinard G, 
Annable L, 
Serrano M, 
Albert JM, 
Charette R. 
Amitriptyline‐perphenazine interaction in ambulatory schizophrenic patients. A controlled study of drug interaction. 
Archives of General Psychiatry 1975;32:1295‐307.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">1101843</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Chouinard 1977 {published data only}</Title>
          <Reference>
            <Citation>Chouinard G, 
Annable L. 
Phenothiazine‐induced ECG abnormalities. Effect of a glucose load. 
Archives of General Psychiatry 1977;34(8):951‐4.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">329786</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Collins 1967 {published data only}</Title>
          <Reference>
            <Citation>Collins AD, 
Dundas J. 
A double‐blind trial of amitriptyline‐perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics. 
British Journal of Psychiatry 1967;113:1425‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4865295</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Dehnel 1968 {published data only}</Title>
          <Reference>
            <Citation>Dehnel LL, 
Vestre ND, 
Schiele BC. 
A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population. 
Current Therapeutic Research, Clinical and Experimental 1968; Vol. 10, issue 4:169‐76. 
[DEHNEL: 1968]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4967871</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Eckmann 1984 {unpublished data only}</Title>
          <Reference>
            <Citation>Eckmann F, 
Weber J. 
No English version available [Vergleich zwischen Perphenazin und Benperidol. Eine kontrollierte Doppelblind‐Studie]. 
unpublished manuscript 1984.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Fruensgaard 1978 {published data only}</Title>
          <Reference>
            <Citation>Fruensgaard K, 
Wollenberg J, 
Hansen KM, 
Fensbo C, 
Sihm F. 
Loxapine versus perphenazine in psychotic patients. A double‐blind, randomized, multicentre trial. 
Current Medical Research and Opinion 1978;5(8):601‐7.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">361345</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hanlon 1964 {published data only}</Title>
          <Reference>
            <Citation>Hanlon TE, 
Nussbaum K, 
Wittig B, 
Hanlon DD, 
Kurland AA. 
The comparative effectiveness of amitriptyline, perphenazine, and their combination in the treatment of chronic psychotic female patients. 
Journal of New Drugs 1964;4:52‐60.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">14157086</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hanlon 1965 {published data only}</Title>
          <Reference>
            <Citation>Hanlon TE, 
Michaux MH, 
Ota KY, 
Shaffer JW, 
Kurland AA. 
The comparative effectiveness of eight phenothiazines. 
Psychopharmacologia 1965;7(2):89‐106.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">5318926</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hoyberg 1993 {published data only}</Title>
          <Reference>
            <Citation>Hoyberg OJ, 
Fensbo C, 
Remvig J, 
Lingjaerde O, 
Sloth Nielsen M, 
Salvesen I. 
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. 
Acta Psychiatrica Scandinavica 1993;88(6):395‐402.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">7508675</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Imai 1980 {published data only}</Title>
          <Reference>
            <Citation>Imai H, 
Nakamura M, 
Fukui Y, 
et al. 
Comparison of efficacy of zotepine and perphenazine in schizophrenia by double‐blind, controlled study. 
Shinkei Seishin Yakuri 1980;2(3):285‐99.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Itoh 1969 {published data only}</Title>
          <Reference>
            <Citation>Itoh H, 
Okamoto M, 
Miura S, 
Suzuki Y, 
Takemasa K, 
Shigeta M, 
et al. 
A comparison between the clinical effectiveness of a dibenzothiazepine derivative and a phenothiazine derivative in schizophrenia. A controlled double blind study using clotiapine (W 130) and perphenazine. 
Seishin Igaku 1969;11(6):465‐75.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Itoh 1969 II {published data only}</Title>
          <Reference>
            <Citation>Itoh H, 
Miura S, 
Asai M, 
et al. 
Comparison of thiothixene and perphenazine in schizophrenic patients using double‐blind technique. 
Seishin Igaku 1969;11(4):284‐97.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Itoh 1969 III {published data only}</Title>
          <Reference>
            <Citation>Itoh H, 
Okamoto M, 
Miura S, 
et al. 
Comparison of a butyrophenone derivative (methylperidol) and a phenothiazine derivative (perphenazine) in schizophrenic patients using double‐blind technique: statistical analysis by sequential method and wilcoxon test. 
Seishin Igaku 1969;11(2):131‐42.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Itoh 1976 {published data only}</Title>
          <Reference>
            <Citation>Itoh H, 
Miura S, 
Yagi G, 
Ogita K, 
Ohtsuka N, 
Koga Y, 
et al. 
Comparison of clinical effects of penfluridol, a long‐acting oral neuroleptic, and perphenazine in schizophrenia using double‐blind technique. 
Rinsho Hyoka 1976;4(1):101‐29.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kane 2003 {published data only}</Title>
          <Reference>
            <Citation>Bristol‐Myers S. 
A multicenter, randomized, double‐blind study of flexible doses of aripiprazole versus perphenazine in the treatment of patients with treatment‐resistant schizophrenia. 
http://www.clinicalstudyresults.org/ 2004. 
[BRISTOL‐MYERS: 2004]
</Citation>
          </Reference>
          <Reference>
            <Citation>Gismondi R, 
Meltzer H, 
Kujawa M, 
Carson W, 
Stringfellow J, 
Iwamoto T, 
et al. 
Aripiprazole versus perphenazine in treatment‐resistant schizophrenia. 
Proceedings of the 24th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24; Paris, France 2004. 
[KANE: 2003 a]
</Citation>
          </Reference>
          <Reference>
            <Citation>Kane J, 
Carson W, 
Kujawa M, 
Stringfellow J, 
Marcus R, 
Sanchez R, 
et al. 
Aripiprazole in treatment‐resistant schizophrenia: a 6‐week double‐ blind comparison study versus perphenazine. 
Schizophrenia Research 2004; Vol. 67, issue 1:155‐6. 
[KANE: 2003 a]
</Citation>
          </Reference>
          <Reference>
            <Citation>Kane J, 
Carson WH, 
Kujawa M, 
Stringfellow J, 
Marcus R, 
Sanchez R, 
et al. 
Aripiprazole in treatment‐resistant schizophrenia: A 6‐week double‐blind comparison study versus perphenazine. 
Conference proceedings. Elsevier Science Bv, 2004:155‐6. 
[KANE: 2004a]
</Citation>
          </Reference>
          <Reference>
            <Citation>Kane J, 
McQuade R, 
Jody D, 
Carson W, 
Kujawa M, 
Stringfellow J, 
et al. 
Aripiprazole in treatment‐resistant schizophrenia: a 6‐week double‐blind comparison study vs perphenazine. 
Conference proceedings: 12th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland 2004. 
[KANE: 2003 a]
</Citation>
          </Reference>
          <Reference>
            <Citation>Kane JM, 
Meltzer HY, 
Carson WH Jr, 
McQuade RD, 
Marcus RN, 
Sanchez R. Aripiprazole Study Group. 
Aripiprazole for treatment‐resistant schizophrenia: results of a multicenter, randomized, double‐blind, comparison study versus perphenazine. 
Journal of Clinical Psychiatry 2007; Vol. 68, issue 2:213‐23. 
[KANE: 2007]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17335319</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>McQuade R, 
Jody D, 
Kane J, 
Carson W, 
Kujawa M, 
Stringfellow J, 
et al. 
Efficacy and safety of aripiprazole versus perphenazine in treatment‐resistant schizophrenia. 
European Neuropsychopharmacology 2003; Vol. 13, issue 4:S326. 
[KANE: 2003 a]
</Citation>
          </Reference>
          <Reference>
            <Citation>Modell S, 
Jody D, 
Kujawa M, 
Carson W, 
Stringfellow J, 
Iwamoto T, 
et al. 
Efficacy of aripiprazole and perphenazine in severe schizophrenia resistant to treatment with atypical antipsychotic drugs. 
European Neuropsychopharmacology 2004; Vol. 14, issue Suppl 3:S265. 
[KANE: 2003 a]
</Citation>
          </Reference>
          <Reference>
            <Citation>Sanchez R, 
Meltzer HY, 
Marcus RN, 
Stringfellow J, 
Carson WH, 
Kane JM. 
Aripiprazole versus perphenazine in Treatment ‐ Resistant Schizophrenia. 
Schizophrenia Bulletin 2005; Vol. 31:502. 
[KANE: 2003 a]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kurihara 1983 {published data only}</Title>
          <Reference>
            <Citation>Kurihara M, 
Ito H, 
Kato N, 
et al. 
Clinical evaluation of clocapramine (clofekton) in schizophrenia: a double blind comparison of clocapramine, haloperidol and perphenazine. 
Rinsho Seishin Igaku 1983;12(4):519‐38.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kurland 1961 {published data only}</Title>
          <Reference>
            <Citation>Kurland AA, 
Hanlon TE, 
Tatom MH, 
Ota KY, 
Simopoulos AM. 
The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness. 
Journal of Nervous and Mental Disease 1961;133(1):1‐18.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13755278</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Kurland AA, 
Hanlon TE, 
Tatom MH, 
Simopoulos AM. 
Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations. 
Journal of Nervous and Mental Disease 1961;132:61‐74.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13755279</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Lepola 1989 {published data only}</Title>
          <Reference>
            <Citation>Lepola U, 
Koskinen T, 
Rimon R, 
Salo H, 
Gordin A. 
Sulpiride and perphenazine in schizophrenia. A double‐blind clinical trial. 
Acta Psychatrica Scandinavica 1989;80(1):92‐6.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2669445</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Naukkarinen 2000 {published data only}</Title>
          <Reference>
            <Citation>Eli Lilly, 
Company. 
HGBJ: olz v perphenazine. 
Eli Lilly and Company 2001.
</Citation>
          </Reference>
          <Reference>
            <Citation>Naukkarinen H, 
Rimon R, 
Katila H, 
Riihikangas R, 
Heikkilä L. 
Olanzapine and perphenazine in schizophrenia. 
Schizophrenia Research 2000;41(1):190.
</Citation>
          </Reference>
          <Reference>
            <Citation>Rimon RH. 
Olanzapine versus perphenazine in the treatment of schizophrenia: a double‐blind study. 
Schizophrenia research 2004;67(1):164‐5.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Remvig 1987 {published data only}</Title>
          <Reference>
            <Citation>Remvig J, 
Larsen H, 
Rask P, 
Skausig OB, 
Skov S, 
Strömgren LS. 
Zuclopenthixol and perphenazine in patients with acute psychotic states. A double‐blind multicentre study. 
Pharmacopsychiatry 1987;20:147‐54.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3615572</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Sun 2000 {published data only}</Title>
          <Reference>
            <Citation>Sun Z, 
Liu B, 
Li Z, 
Zhang D, 
et al. 
Clozapine combined with perphenazine in the treatment of schizophrenia [氯氮平联用奋乃静治疗精神分裂症对照研究]. 
Hebei Mental Health 2000; Vol. 13, issue 2:142‐4. 
[SUN: 2000 (Perp)]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Takahashi 1982 {published data only}</Title>
          <Reference>
            <Citation>Takahashi R, 
Inanaga K, 
Samejima K, 
Sarai K, 
Asada S, 
Otsuki S, 
et al. 
Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study. 
Journal of International Medical Research 1982;10(4):257‐67.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">6126413</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Van Praag 1976 {published data only}</Title>
          <Reference>
            <Citation>Praag HM, 
Korf J, 
Dolc LCW. 
Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity. 
British Journal of Psychiatry 1976;129:547‐55.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">1000139</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Wang 2008a {published data only}</Title>
          <Reference>
            <Citation>Wang XD, 
Wang YH, 
Feng TM, 
Liu ML, 
Zhang SX. 
Controlled study of risperidone in elderly treatment of first‐episode schizophrenia [利培酮治疗老年期首发精神分裂症对照研究]. 
Journal of Psychiatry 2008;21(2):141.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Wang 2008b {published data only}</Title>
          <Reference>
            <Citation>Wang RF, 
Yu X, 
Song ZD. 
Schizophrenia olanzapine and perphenazine in the treatment of positive symptoms [奥氮平与奋乃静治疗阳性症状为主的精神分裂症对照研究]. 
Journal of Psychiatry 2008;21(6):423‐4.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Wang 2008c {published data only}</Title>
          <Reference>
            <Citation>Wang X, 
Wu J, 
Chen Z, 
Zhang JF, 
et al. 
Elderly first controlled study of quetiapine in the treatment of schizophrenia [喹硫平治疗首发老年期精神分裂症对照研究]. 
Journal of Psychiatry 2008;21(6):463‐4.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Woggon 1978 {published data only}</Title>
          <Reference>
            <Citation>Woggon B. 
Effects and side‐effects of bromperidol in comparison with other antipsychotic drugs. 
Acta Psychiatrica Belgica 1978;78(1):155‐72.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">347878</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Woggon B, 
Angst J. 
Double‐blind comparison of bromperidol and perphenazine. 
International Pharmacopsychiatry 1978;13:165‐76.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">355182</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Zhang 2010 {published data only}</Title>
          <Reference>
            <Citation>Zhang JL, 
Zhang J, 
Shen B. 
Aripiprazole orally disintegrating tablets in the treatment of schizophrenia in old age were observed [阿立哌唑口腔崩解片治疗老年期精神分裂症疗效的对照观察]. 
Chinese Journal of Modern Drug Application 2010;4(14):119‐20.
</Citation>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>References to studies excluded from this review</Title>
        <ReferenceList>
          <Title>Affleck 1969 {published data only}</Title>
          <Reference>
            <Citation>Affleck JW, 
Cooper AJ, 
Forrest AD, 
Smythies JR, 
Zealley AK. 
Penicillamine and schizophrenia ‐ a clinical trial. 
British Journal of Psychiatry 1969;115(519):173‐6.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4888134</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Ahlfors 1980 {published data only}</Title>
          <Reference>
            <Citation>Ahlfors UG, 
Dencker SJ, 
Gravem A, 
Remvig J. 
Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double‐blind Nordic multicentre trial. 
Acta Psychiatrica Scandinavica Supplementum 1980;279:77‐91.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">6996426</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Akimoto 1966 {published data only}</Title>
          <Reference>
            <Citation>Akimoto H, 
Shimazaki T, 
Shibata N, 
Sato Y, 
Takahashi R, 
Naruse H, 
et al. 
Current status of pharmacotherapy in schizophrenia. 
Folia Psychiatrica et Neurologica Japonica 1966;20(1):1‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">5340822</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Angst 1975 {published data only}</Title>
          <Reference>
            <Citation>Angst J, 
Woggon B. 
Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazine decanoate, flusipirilene, penfluridol, perphenazine enanthate and pipothiazine palmitate. 
Arzneimittel Forschung 1975;25(2):267‐70.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">1091272</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Anonymous 1966 {published data only}</Title>
          <Reference>
            <Citation>Anonymous. 
Schizophrenic and other psychotic reactions. 
Medical Letter 1966:15‐6.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Asada 1976 {published data only}</Title>
          <Reference>
            <Citation>Asada S, 
Ishimaru T, 
Kubo S, 
Kodama H, 
Masuda K. 
Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double‐blind method [Etude des effets cliniques du sulpiride et de la perphenazine chez 82 schizophrenes par la methode du double aveugle]. 
Encephale 1976;2(1):73‐83.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">770152</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bakke 1973 {published data only}</Title>
          <Reference>
            <Citation>Bakke O. 
Clinical experience with depot neuroleptics. 
Acta Psychiatrica Scandinavica Supplementum 1973;246:32‐41.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4588180</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bandelow 1992 {published data only}</Title>
          <Reference>
            <Citation>Bandelow B, 
Muller P, 
Frick U, 
Gaebel W, 
Linden M, 
Muller Spahn F, 
et al. 
Depressive syndromes in schizophrenic patients under neuroleptic therapy. 
European Archives of Psychiatry and Clinical Neuroscience 1992; Vol. 241, issue 5:291‐5. 
[BANDELOW: 1992]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">1351405</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Becker 1970 {published data only}</Title>
          <Reference>
            <Citation>Becker RE. 
Evaluation of an amitriptyline‐perphenazine combination in chronic schizophrenia. 
American Journal of Psychiatry 1970;127(6):827‐131.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4921622</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bjerkelund 1965 {published data only}</Title>
          <Reference>
            <Citation>Bjerkelund C, 
Nitter‐Hauge S, 
Jakobsen E. 
Perphenazine (trilafon) in the prophylaxis of nausea and vomiting following acute myocardial infarct. 
Acta Medica Scandinavica 1965;177:729‐37.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">14334666</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Böhlau 1985 {published data only}</Title>
          <Reference>
            <Citation>Böhlau V, 
Weber J. 
No English title available [Therapie dementieller Prozesse bei Alterspatienten]. 
Therapiewoche 1985;35(47):5445‐8.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Cannistra 1959 {published data only}</Title>
          <Reference>
            <Citation>Cannistra F, 
Abrams AA. 
Perphenazine in obstetrics. Evaluation of its use to replace an analgesic. 
Obstetrics and Gynecology 1959;14(3):337‐41.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13807454</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Ceskova 1994 {published data only}</Title>
          <Reference>
            <Citation>Ceskova E, 
Svestka J. 
Risperidone vs. perphenazine ‐ a double‐blind comparison and prolactine plasma levels [Risperidone gegen Rispehenazine ‐ ein doppelt‐blinder Vergleich und Prolaktin‐Plasmaspiegel]. 
Psychiatria Danubina 1994;6(3‐4):151‐5.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Ceskova 1996 {published data only}</Title>
          <Reference>
            <Citation>Ceskova E, 
Svestka J. 
Efficacy and tolerability of risperidone in different dose levels [Ucinnost a snasenlivost risperidonu pri ruznem davkovani (sdeleni z praxe)]. 
Ceskoslovenska Psychiatrie 1996;92(1):50‐6.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">8768938</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Clarke 1981 {published data only}</Title>
          <Reference>
            <Citation>Clarke JMC. 
Amitriptyline and perphenazine (triptafen DA) in chronic pain. 
Anaesthesia 1981;36:210‐2.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">7212233</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Cohen 1958 {published data only}</Title>
          <Reference>
            <Citation>Cohen H. 
Trilafon in the treatment of chronically psychotic hospitalized patients. 
Prüfbericht, New York. E. Merck Darmstadt 1958.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13583248</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Cooper 1979 {published data only}</Title>
          <Reference>
            <Citation>Cooper SF, 
Dugal R, 
Elie R, 
Albert JM. 
Metabolic interaction between amitriptyline and perphenazine in psychiatric patients. 
Neuro‐Psychopharmacology 1979;3:369‐76.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">400992</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Den Boer 2000 {published data only}</Title>
          <Reference>
            <Citation>Boer JA, 
Vahlne J‐O, 
Post P, 
Heck AH, 
Daubenton F, 
Olbrich R. 
Ritanserin as add‐on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. 
Human Psychopharmacology 2000;15:179‐89.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">12404331</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Dencker 1994 {published data only}</Title>
          <Reference>
            <Citation>Dencker SJ, 
Gios I, 
Martenson E, 
Norden T, 
Nyberg G, 
Persson R, 
et al. 
A long‐term cross‐over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. 
Psychopharmacology 1994;114(1):24‐30.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">7846204</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Eklund 1976 {published data only}</Title>
          <Reference>
            <Citation>Eklund KL. 
A double‐blind comparison study between penfluridol and perphenazine in acute schizophrenic patients. 
Nordisk Psykiatrisk Tidsskrift 1976;30(5):384‐91.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Erb 1982 {published data only}</Title>
          <Reference>
            <Citation>Erb RJ, 
Stoltman WP. 
Serum prolactin level increase in normal subjects following administration of perphenazine oral dosage forms: possible application to bioavailibility testing. 
Journal of Pharmaceutical Sciences 1982;71(8):883‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">7120089</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Eufe 1979 {published data only}</Title>
          <Reference>
            <Citation>Eufe R, 
Wegener G. 
Double‐blind comparison of two depot neuroleptics (perphenazine enanthate and flupentixol enanthate) in chronic schizophrenia. 
Nervenarzt 1979;50(8):534‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">394015</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Fahn 1964 {published data only}</Title>
          <Reference>
            <Citation>Fahn S. 
Treatment of choreic movements with perphenazine. 
Diseases of The Nervous System 1972;33:653‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4265163</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Farzin 2005 {published data only}</Title>
          <Reference>
            <Citation>Farzin D, 
Hosseini SH, 
Shafaat A. 
A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia. 
Iranian Journal of Medical Sciences 2005; Vol. 30, issue 2:59‐62. 
[FARZIN: 2005]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Fitzgerald 1969 {published data only}</Title>
          <Reference>
            <Citation>Fitzgerald CH. 
A double‐blind comparison of haloperidol with perphenazine in acute psychiatric patients. 
Current Therapeutic Research 1969;11(8):515‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4979702</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Galdi 1988 {published data only}</Title>
          <Reference>
            <Citation>Galdi J, 
Bonato RB. 
Relationship of adverse drug reactions to length of hospital‐stay in genetically subgrouped schizophrenics. 
Canadian Journal of Psychiatry 1988;33(9):816‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2905632</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Gerlach 1977 {published data only}</Title>
          <Reference>
            <Citation>Gerlach J, 
Rasmussen PT, 
Hansen L, 
Kristjansen P. 
Antiparkinsonian agents and long‐term neuroleptic treatment. Effect of G31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety. 
Acta Psychiatrica Scandinavica 1977;55(4):251‐60.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">324238</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Gerlach 1988 {published data only}</Title>
          <Reference>
            <Citation>Gerlach J. 
Tardive dyskinesia:Pathophysiological mechanisms and clinical trials. 
L'Encephale 1988;14:227‐232.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2905651</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Gerson 1964 {published data only}</Title>
          <Reference>
            <Citation>Gerson IM, 
Chat E, 
Twigger NA. 
Clinical trial of a potentiated diketopiperazine derivative as a psychopharmacological agent for the treatment of psychotic patients. 
American Journal of Psychiatry 1964;121:179‐81.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">14196596</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Gianelli 1990 {published data only}</Title>
          <Reference>
            <Citation>Gianelli A, 
Rabboni M, 
Zarattini F. 
No English title available [Profili clinici di azione, indicazioni preferenziali, effeti terapeutici e contraindicazioni di tre neuroletti depot in trial multicentro di confronto]. 
Rivista di Psichiatria 1990;25(1):7‐24.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hadlik 1970 {published data only}</Title>
          <Reference>
            <Citation>Hadlik J, 
Svestka J, 
Nahunek K, 
Rodova A. 
Controlled studies with thiothixene and perphenzine in schizophrenic psychoses [Kontrolovana studie s thiothixenem a perfenazinem u psychoz schizofrenniho okruhu]. 
Activitas Nervosa Superior 1970;12(1):60‐1.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4907392</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hanlon 1966 {published data only}</Title>
          <Reference>
            <Citation>Hanlon T. 
Perphenazine‐benztropine mesylate treatment of newly admitted psychiatric patients. 
Psychopharmacologia 1966; Vol. 9, issue 4:328‐39. 
[HANLON: 1966]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4874349</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hansen 1979 {published data only}</Title>
          <Reference>
            <Citation>Hansen BL, 
Elley J, 
Christensen RT, 
Laersen NE, 
Naestoft J, 
Hvidberg EF. 
Plasma levels of perphenazine and its metabolites during simultaneous treatment with anticholinergic drugs. 
British Journal of clinical Pharmacology 1979;7:75‐80.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC1429600</ArticleId>
              <ArticleId IdType="pubmed">760745</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Haran 1960 {published data only}</Title>
          <Reference>
            <Citation>Haran T. 
Perphenazine (Fentazine) in the management of chronic schizophrenia. 
Journal of the Irish Medical Association 1960;46:135‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">14399668</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Holden 1969 {published data only}</Title>
          <Reference>
            <Citation>Holden JM, 
Itil TM, 
Keskiner A. 
Comparison of perphenazine and P‐5227 in chronic schizophrenics: clinical and EEG effects. 
Journal of Clinical Pharmacology and the Journal of New Drugs 1969;9(3):163‐75.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">5255181</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hollister 1967 II {published data only}</Title>
          <Reference>
            <Citation>Hollister LE, 
Overall JE, 
Shelton J, 
Pennington V, 
Kimbell I, 
Johnson M. 
Drug therapy of depression. 
Archives of General Psychiatry 1967;17:486‐93.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4861381</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hollister 1974 {published data only}</Title>
          <Reference>
            <Citation>Hollister LE, 
Overall JE, 
Kimbell I Jr, 
Pokorny A. 
Specific indications for different classes of phenothiazines. 
Archives of General Psychiatry 1974;30(1):94‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4148660</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Huang 1964 {published data only}</Title>
          <Reference>
            <Citation>Huang CL, 
Kurland AA. 
Perphenazine (trilafon) metabolism in psychotic patients. 
Archives of General Psychiatry 1964;10:639‐46.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">14159263</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Jprn 2011 {published data only}</Title>
          <Reference>
            <Citation>Jprn U. 
An intervention study of optimizing algorism‐based pharmacological treatment for schizophrenia. 
http://www.umin.ac.jp/ctr/index.htm 2011. 
[UMIN000004931]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kaim 1972 {published data only}</Title>
          <Reference>
            <Citation>Kaim SC, 
Klett CJ. 
Treatment of delirium tremens. A comparative evaluation of four drugs. 
Quarterly Journal of Studies 1972;33:1065‐72.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4567595</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kaji 1974 {published data only}</Title>
          <Reference>
            <Citation>Kaji S, 
Tsukada K, 
Hasegawa S, 
et al. 
Comparison of clinical efficacy of clocapramine and perphenazine for chronic schizophrenia by the double‐blind study. 
Rinsyo Seisin Igaku 1974;3(8):867‐74.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kawakita 1965 {published data only}</Title>
          <Reference>
            <Citation>Kawakita Y. 
Drug therapy of acute schizophrenia. 
Saishin Igaku 1965;20(9):2440‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">5329115</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kistrup 1991 {published data only}</Title>
          <Reference>
            <Citation>Kistrup K, 
Gerlach J, 
Aaes Jorgensen T, 
Larsen NE. 
Perphenazine decanoate and cis(z)‐flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose. 
Psychopharmacology 1991;105(1):42‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">1745710</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kline 1968 {published data only}</Title>
          <Reference>
            <Citation>Kline NS, 
Blair J, 
Cooper TB, 
Esser AH, 
Hackett E, 
Vestergaard P. 
A controlled seven year study of endocrine and other indices in drug treated chronic schizophrenics. 
Acta Psychiatrica Scandinavica Supplementum 1968;206:7‐75.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4890732</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Knudsen 1985 {published data only}</Title>
          <Reference>
            <Citation>Knudsen P, 
Hansen LB, 
Auken G, 
Waehrens J, 
Højholdt K, 
Larsen NE. 
Perphenazine decanoate vs. Perphenazine enanthate ‐ efficacy and side‐effects in a 6 week double‐blind, comparative study of 50 drug monitored psychotic patients. 
Acta Psychiatrica Scandinavica Supplementum 1985;322:15‐28.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3907278</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Knudsen 1985a {published data only}</Title>
          <Reference>
            <Citation>Knudsen P, 
Hansen LB, 
Hojholdt K, 
Larsen NE. 
Long‐term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients. 
Acta Psychiatrica Scandinavica. Supplementum 1985; Vol. 322:29‐40. 
[KNUDSEN: 1985 b]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3907279</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Knudsen P, 
Hansen LB, 
Hojholdt K, 
Larsen NE. 
Long‐term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients. 
Acta Psychiatrica Scandinavica. Supplementum 1985; Vol. 322:41‐50. 
[KNUDSEN: 1985 b]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3934921</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kothari 1960 {published data only}</Title>
          <Reference>
            <Citation>Kothari NJ, 
Saunders JC, 
Kline NS, 
Griffen JA. 
A comparison of perphenazine, proketazine, nialamide and MO‐482 in chronic schizophrenics. 
American Journal of Psychiatry 1960;117:358‐60.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13753478</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Lapolla 1967 {published data only}</Title>
          <Reference>
            <Citation>Lapolla A. 
A double‐blind evaluation of chlorpromazine versus a combination of perphenazine and amitriptyline. 
International Journal of Neuropsychiatry. 1967; Vol. 3, issue 5:403‐5.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Levine 1997 {published data only}</Title>
          <Reference>
            <Citation>Levine J, 
Caspi N, 
Laufer N. 
Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients. 
Schizophrenia Research 1997;26:55‐63.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">9376337</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Lindholm 1978 {published data only}</Title>
          <Reference>
            <Citation>Lindholm H, 
Gullberg B, 
Ohman A, 
Sedvall G. 
Effects of perphenazine injections on prolactin levels in plasma from schizophrenic women and men. 
Psychopharmacology 1978;57(1):1‐4.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">96459</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Linnoila1982 {published data only}</Title>
          <Reference>
            <Citation>Linnoila M, 
George L, 
Guthrie S. 
Interaction between antidepressants and perphenazine in psychiatric inpatients. 
American Journal of Psychiatry 1982;139(10):1329‐31.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">7124987</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Loprete 1967 {published data only}</Title>
          <Reference>
            <Citation>Loprete FP, 
Palm C. 
Sleep in psychotic patients: a comparative clinical study. 
International journal of neuropsychiatry 1967;3(6):497‐500.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4868302</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Mason‐Browne 1957 {published data only}</Title>
          <Reference>
            <Citation>Mason‐Browne NL. 
Perphenazine ‐ a drug modifying consciousness. 
American Journal of Psychiatry 1957;114:173‐4.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13444487</ArticleId>
            </ArticleIdList>
          </Reference>
          <Reference>
            <Citation>Mason‐Browne NL, 
Borthwick JW. 
Effect of perphenazine (trilafon) on modification of crude consciousness. 
Diseases of the Nervous System 1957;18:300‐6.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13447809</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Mazurek 2003 {published data only}</Title>
          <Reference>
            <Citation>Mazurek I, 
Loza B, 
Lecyk A. 
Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia. 
European Neuropsychopharmacology 2003; Vol. 13, issue 4:S347. 
[LOZA: 2001]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Moore 1958 {published data only}</Title>
          <Reference>
            <Citation>Moore DC, 
Bridenbaugh LD, 
Ackeren van EG, 
Cole EV. 
Control of postoperative vomiting with perphenazine (trilafone): a double‐blind study. 
Anesthesiology 1958;19:72‐4.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13498384</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Müller 1994 {published data only}</Title>
          <Reference>
            <Citation>Müller M. 
Pharmacokinetik/Bioavailibility Evaluation of Three Different perphenazine Formulations (Decentan) in 18 healthy volunteers [Pharmakokinetik/Bioverfügbarkeits‐Studie mit drei verschiedenen Perphenazin‐Zubereitungen (Decentan) mit 18 gesunden Freiwilligen]. 
E. Merck, Darmstadt 1994.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Nahunek 1967 {published data only}</Title>
          <Reference>
            <Citation>Nahunek K, 
Svestka J, 
Misurec J. 
Clinical comparison of methophenazine and perphenazine in schizophrenia. A controlled study. Effects on the photomyoclonic threshold [Klinischer Vergleich von Methophrenazin (Frenolon) und Perphenazin bei Schizophrenie. Kontrollierte Studie. Beeinflussung der photomyoklonischen Schwelle]. 
Activitas Nervosa Superior 1967;9(4):404‐5.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4889075</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Nahunek 1968 {published data only}</Title>
          <Reference>
            <Citation>Nahunek K, 
Svestka J, 
Rodova A. 
Clinical experience with octoclothepin in psychoses. Comparasion with perphenazine. 
Activitas Nervosa Superior 1968;10(3):339‐40.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4883242</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Nahunek 1969 {published data only}</Title>
          <Reference>
            <Citation>Nahunek K, 
Hadlik J, 
Svestka J, 
Rodova A, 
Vanysek J. 
A comparison of therapeutic effects of triperidol and perphenazine in schizophrenia [Srovnani lecebneho ucinku triperidolu s perphenazinem u schizofrenie]. 
Ceskoslovenska Psychiatrie. 1969;65(5):281‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">5363280</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Nahunek 1970 {published data only}</Title>
          <Reference>
            <Citation>Nahunek K, 
Hadlik J, 
Rodova A, 
Misurec J, 
Vanysek J. 
Comparison of triperidol with perphenazine in schizophrenic psychoses. Effect on the photomyoclonic threshold [Srovnani triperidolu s perphenazinem u schizofrennich psychoz vliv na fotomyoklonicky prah]. 
Activitas Nervosa Superior 1970;12(1):56‐7.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4907390</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Nahunek 1970 II {published data only}</Title>
          <Reference>
            <Citation>Nahunek K, 
Svestka J, 
Rodova A. 
Comparison of the therapeutic effect of flupenthixol and perphenazine in schizophrenia. 
Activitas Nervosa Superior 1970;12(3):247‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">5457440</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Nahunek 1975 {published data only}</Title>
          <Reference>
            <Citation>Nahunek K, 
Svestka J, 
Misurec J, 
Rodova A. 
Clinical experience with clozapin [Klinicke zkusenosti s clozapinem]. 
Ceskoslovenska Psychiatrie 1975;71(1):11‐20.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">1093728</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Nahunek 1976 {published data only}</Title>
          <Reference>
            <Citation>Nahunek K, 
Rodova A, 
Svestka J. 
Outline classification of neuroleptic drugs based on results of short‐term control crossed studies in schizophrenia [Pokus o klasifikaci neuroleptik na podklade vysledku kradkodobych kontrolovanych zkrizenyich studii u schizofrenie]. 
Ceskoslovenska Psychiatrie 1976;72(2):104‐14.
</Citation>
          </Reference>
          <Reference>
            <Citation>Nahunek K, 
Svestka J, 
Ceskova E. 
On the question of differences between therapeutic responses after particular neuroleptics in comparison to perphenazine in schizophrenics [Kotazce rozdilnosti terapeutickych odpovedi po jednotlivych neurolepticich ve srovnani s perphenazinem u schizofrennich nemocnych]. 
Ceskoslovenska Psychiatrie 1981;77(1):25‐30.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">6113897</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Nahunek 1980 {published data only}</Title>
          <Reference>
            <Citation>Nahunek K, 
Svestka J, 
Ceskova E. 
Controlled 'comparison' of perphenazine with perphenazine in schizophrenia ‐ a methodical check of a double‐blind cross‐over design. 
Activitas Nervosa Superior 1980;22(3):154‐5.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Nordic DS Group 1986 {published data only}</Title>
          <Reference>
            <Citation>Nordic Dyskinesia Study Group. 
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicentre study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. 
Psychopharmacology 1986;90(4):423‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2880362</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>O'Reilly 1957 {published data only}</Title>
          <Reference>
            <Citation>O'Reilly PO, 
Wojcicki HM, 
Hrychuk W, 
Keogh RP. 
Perphenazine (Trilafon) in the treatment of pschoses. 
Canadian Medical Association Journal 1957;77:952‐5.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC1824174</ArticleId>
              <ArticleId IdType="pubmed">13479850</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Oltman 1966 {published data only}</Title>
          <Reference>
            <Citation>Oltman JE, 
Friedman S. 
Perphenazine‐amitriptyline in the treatment of schizophrenia. 
American Journal of Psychiatry 1966;123(5):607‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">5331928</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Omerov 1989 {published data only}</Title>
          <Reference>
            <Citation>Omerov M, 
Wistedt B, 
Bolvig HL, 
Larsen NE. 
The relationship between perphenazine plasma levels and clinical response in acute schizophrenia. 
Progress in Neuropsychopharmacology and Biological Psychiatry 1989;13(1‐2):159‐66.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2664884</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Opjordsmoen 2000 {published data only}</Title>
          <Reference>
            <Citation>Opjordsmoen S, 
Brunsvik S, 
Melle I, 
Dahl A, 
Friis S, 
Haahr U, 
et al. 
A comparison between novel and traditional antipsychotic drugs as first‐line medication in early psychosis. 
Second international conference on early psychosis 2000, 31 March ‐ 2 April. 
[OPJORDSMOEN: 2000]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Pfeiffer 1965 {published data only}</Title>
          <Reference>
            <Citation>Pfeiffer CC, 
Goldstein L, 
Murphree HB, 
Sugerman AA. 
Time‐series frequency analysis, and electrogenesis of the EEGs of normals and psychotics before and after drugs. 
American Journal of Psychiatry. 1965;122:1147‐55.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">14286047</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Prien 1973 {published data only}</Title>
          <Reference>
            <Citation>Prien RF, 
Gillis RD, 
Caffey EM. 
Intermittent pharmacotherapy in chronic schizophrenia. 
Hospital and Community Psychiatry 1973;24(5):317‐322.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4574574</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Prusoff 1979 {published data only}</Title>
          <Reference>
            <Citation>Prusoff BA, 
Williams DH, 
Weissman MM, 
Astrachan BM. 
A controlled clinical trial of amitriptyline added to perphenazine in the treatment of depressed schizophrenics. 
Psychopharmacology Bulletin 1979;15(2):80‐1.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">373008</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Rapp 1972 {published data only}</Title>
          <Reference>
            <Citation>Rapp W. 
Preliminary study of perphenazine enanthate in the treatment of chronic schizophrenia. 
Pharmakopsychiatrie Neuropsychopharmakologie 1972;5:205‐14.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Rapp 1986 {published data only}</Title>
          <Reference>
            <Citation>Rapp W, 
Hellbom E, 
Norrman O, 
Palm U, 
et al. 
A double blind crossover study comparing haloperidol decanoate and perphenazine enanthate. 
Current Therapeutic Research 1986;39(5):665‐70.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Rappaport 1967 {published data only}</Title>
          <Reference>
            <Citation>Rappaport M. 
Competing voice messages. Effects of a message load and drugs on the ability of acute schizophrenics to attend. 
Archives of General Psychiatry 1967;17:97‐103.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4952167</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Rappaport 1968 {published data only}</Title>
          <Reference>
            <Citation>Rappaport M. 
Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background. 
Journal of Nervous and Mental Disease 1968;146(5):404‐11.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">5653878</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Reznik 2000 {published data only}</Title>
          <Reference>
            <Citation>Reznik I, 
Sirota P. 
Treatment of obsessive and compulsive symptoms in schizophrenia with SSRI's and neuroleptics: a randomized controlled trial. 
21st Congress of Collegium Internationale Neuro‐psychopharmacologicum, Glasgow, Scotland, UK 1998.
</Citation>
          </Reference>
          <Reference>
            <Citation>Reznik I, 
Sirota P, 
Psych M. 
Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. 
Journal of Clinical Psychopharmacology 2000;20(4):410‐6.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">10917401</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Rickels 1982 {published data only}</Title>
          <Reference>
            <Citation>Rickels K, 
Csanalosi I, 
Werblowsky J, 
Weise CC, 
Weinstock R, 
Brown AS. 
Amitriptyline‐perphenazine and doxepin in depressed outpatients: a controlled double‐blind study. 
Journal of Clinical Psychiatry 1982;43(10):419‐22.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">6749826</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Ritter 1971 {published data only}</Title>
          <Reference>
            <Citation>Ritter RM, 
Davidson DE. 
Haloperidol for acute psychiatric emergencies. A double‐blind comparison with perphenazine in acute alcoholic psychosis. 
Southern Medical Journal 1971;64(2):249‐50.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4927220</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Rodova 1971 {published data only}</Title>
          <Reference>
            <Citation>Rodova A, 
Nahunek K, 
Svestka J. 
Comparison of the therapeutic results of clothiapin and perphenazine in schizophrenia. 
Activitas Nervosa Superior 1971;13(3):171‐3.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4939829</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Rodova 1973 {published data only}</Title>
          <Reference>
            <Citation>Rodova A, 
Svestka J, 
Nahunek K, 
Ceskova E. 
A blind comparison of clozapine and perphenazine in schizophrenics. 
Activitas Nervosa Superior 1973;15(2):94‐5.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4752682</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Scurr 1958 {published data only}</Title>
          <Reference>
            <Citation>Scurr CF, 
Robbie DS. 
Trials of perphenazine in the prevention of postoperative vomiting. 
British Medical Journal 1958;1:922‐3.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2028360</ArticleId>
              <ArticleId IdType="pubmed">13523229</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Shalev 1993 {published data only}</Title>
          <Reference>
            <Citation>Shalev A, 
Hermesh H, 
Rothberg J, 
Munitz H. 
Poor neuroleptic response in acutely exacerbated schizophrenic patients. 
Acta Psychiatrica Scandinavica 1993;87(2):86‐91.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">8095362</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Sharpley 1964 {published data only}</Title>
          <Reference>
            <Citation>Sharpley P, 
Heistad G, 
Schiele BC. 
Comparison of butaperazine and perphenazine: a double‐blind controlled study. 
Psychopharmacology 1964; Vol. 13:209‐16. 
[SHARPLEY: 1964 a]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">14138756</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Shiloh 2002 {published data only}</Title>
          <Reference>
            <Citation>Shiloh R, 
Zemishlany Z, 
Aizenberg D, 
Valevski A, 
Bodinger L, 
Munitz H, 
et al. 
Mianserin or placebo as adjuncts to typical antipsychotic drugs in resistant schizophrenia. 
International Clinical Psychopharmacology 2002; Vol. 17, issue 2:59‐64. 
[SHILOH: 2002]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">11890187</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Silver 2000 {published data only}</Title>
          <Reference>
            <Citation>Silver H, 
Barash I, 
Aharon N, 
Kaplan A, 
Poyurovsky M. 
Fluvoxamine augmentation of antipsychotic drugs improves negative symptoms in psychotic chronic schizophrenic patients: a placebo‐controlled study. 
International Clinical Psychopharmacology 2000;15(5):257‐61.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">10993127</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Simopoulos 1971 {published data only}</Title>
          <Reference>
            <Citation>Simopoulos AM, 
Pinto A, 
Uhlenhuth EH, 
Mcgee J. 
Old wine in new bottles: decreased hostility in chronic psychotic inpatients treated with diphenylhydantoin (Dilantin). 
5th World Congress of Psychiatry, Ciudad de Mexico. 1971:526.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Simpson 1970 {published data only}</Title>
          <Reference>
            <Citation>Simpson GM, 
Krakov L, 
Kunz‐Bartholini E. 
A controlled trial of combined medications on behavioral and extrapyramidal effects. 
Acta Psychiatrica Scandinavica Supplementum 1970;212:20‐7.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4917968</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Smith 1959 {published data only}</Title>
          <Reference>
            <Citation>Smith JA, 
Christian D, 
Mansfield E, 
Figaredo A. 
A graphic comparison of five phenothiazines. 
American Journal of Psychiatry 1959;116:392‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13831998</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Spiker 1985 {published data only}</Title>
          <Reference>
            <Citation>Spiker DG, 
Cofsky Weiss J, 
Dealy RS, 
Griffin SJ, 
Hanin I, 
Neil JF, 
et al. 
The pharmacological treatment of delusional depression. 
American Journal of Psychiatry 1985;142:430‐6.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3883815</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Sun 2010 {published data only}</Title>
          <Reference>
            <Citation>Sun S, 
Liu Y, 
Long JL, 
Wang L. 
Venlafaxine extended release tablets on schizophrenia cognitive function] Google Translate. 
Chinese Journal of Health Psychology [中国健康心理学杂志] 2010; Vol. 18, issue 4:394‐6. 
[孙群星//刘勇//龙金亮//王: 2010]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Sun 2010b {published data only}</Title>
          <Reference>
            <Citation>Sun J, 
Xie S, 
Nisu L, 
Wang X, 
Shang X, 
et al. 
acute schizophrenic inpatients converted to aripiprazole treatment efficacy and safety of] Google Translate [急性期精神分裂症住院患者转换为阿立哌唑治疗疗效及安全性研究]. 
Shandong Archives of Psychiatry [山东精神医学] 2010; Vol. 23, issue 3:179‐81. 
[孙静//谢世平//倪苏琳//王: 2010]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Svestka 1970 {published data only}</Title>
          <Reference>
            <Citation>Svestka J, 
Nahunek K. 
Controlled comparative study of methylperidol and perphenazine in schizophrenic psychoses [Kontrolovane srovnani metylperidolu s perfenazinem u psychoz schizofrenniho ikruhu]. 
Activitas Nervosa Superior 1970;12(1):57‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4907391</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Svestka 1972 {published data only}</Title>
          <Reference>
            <Citation>Svestka J, 
Nahunek K. 
A comparison of pimozide with perphenazine in the treatment of acute schizophrenic psychoses. 
Activitas Nervositas Superior 1972;14(2):93‐4.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4557145</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Svestka 1973 {published data only}</Title>
          <Reference>
            <Citation>Svestka J, 
Rodova A, 
Nahunek K. 
Comparison of the short‐term therapeutic effect of oxyprothepine and perphenazine in schizophrenic patients. A controlled study. 
Activitas Nervosa Superior 1973;15(2):103‐4.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4591602</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Svestka 1974 {published data only}</Title>
          <Reference>
            <Citation>Svestka J, 
Nahunek K, 
Rodova A, 
Ceskova E. 
A controlled comparison of oxypertine and perphenazine in schizophrenic psychoses. 
Activitas Nervosa Superior 1974;16(3):165‐6.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4608706</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Svestka 1975 {published data only}</Title>
          <Reference>
            <Citation>Svestka J, 
Nahunek K, 
Rodova A, 
Ceskova E. 
The position of trifluoperazine in the group of neuroleptics (a controlled clinical comparative study). 
Activitas Nervosa Superior 1975;17(3):208.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">1106107</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Svestka 1989 {published data only}</Title>
          <Reference>
            <Citation>Svestka J, 
Nahunek K, 
Ceskova E, 
Rysanek R, 
Balsíková, 
J. 
Controlled cross over comparison of isofloxythepin and perphenazine in the treatment of schizophrenic psychoses. 
Activitas Nervosa Superior 1989;31(1):32‐4.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2571218</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Svestka 1989a {published data only}</Title>
          <Reference>
            <Citation>Svestka J, 
Ceskova E, 
Rysanek R, 
Nahunek K. 
Controlled cross over comparison of carbamazepine with perphenazine in schizophrenic psychoses. 31st Annual Psychopharmacology Meeting (1989, Jesenik, Czechoslovakia). 
Activitas Nervosa Superior 1989;31(4):276‐7.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2576922</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Svestka 1990 {published data only}</Title>
          <Reference>
            <Citation>Svestka J, 
Rysanek R, 
Nahunek K, 
Ceskova E. 
Therapeutic results in schizophrenic and schizoaffective psychoses with sulpiride (Eglonyl Alkaloid), as compared with perphenazine (Perfenazin Spofa) [Vysledky lecby schizofrennich a schizoafektivnich nemocnych sulpiridem (Eglonyl Alkaloid) ve srovnani s perfenazinem (Perfenazin Spofa)]. 
Ceskoslovenska Psychiatrie 1990;86(3):145‐56.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">2225184</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Syvalahti 1997 {published data only}</Title>
          <Reference>
            <Citation>Syvalahti EK, 
Taiminen T, 
Saarijarvi S, 
Lehto H, 
Niemi H, 
Ahola V, 
et al. 
Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. 
Journal of International Medical Research 1997;25(1):24‐32.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">9027670</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Tegeler 1979 {published data only}</Title>
          <Reference>
            <Citation>Tegeler J, 
Floru L. 
A comparative study of the longacting neuroleptics perphenazine enanthate and flusipirilene. 
Pharmakopsychiatrie Neuropsychopharmakologie 1979;12(5):357‐65.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">504342</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Wang 2001 {published data only}</Title>
          <Reference>
            <Citation>Wang X, 
Yin J, 
Yang L, 
Li W, 
Wu G, 
et al. 
Double‐blind controlled side reaction of the L‐stepholidine the treatment of schizophrenia and Nursing Strategy. 
Shandong Archives of Psychiatry [山东精神医学] 2001; Vol. 14, issue 3:204‐6. 
[王秀英: 2001]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Whittaker 1963 {published data only}</Title>
          <Reference>
            <Citation>Whittaker CB, 
Hoy RM. 
Withdrawal of perphenazine in chronic schizophrenia. 
British Journal of Psychiatry 1963;109:422‐7.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">14000409</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Wolf 2007 {published data only}</Title>
          <Reference>
            <Citation>Wolf J, 
Janssen F, 
Lublin H, 
Salokangas RKR, 
Allain H, 
Smeraldi E, 
et al. 
A prospective, multicentre, open‐label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU‐BETA). 
Current Medical Research and Opinion 2007; Vol. 23, issue 10:2313‐23. 
[WOLF: 2007]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17706003</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Yagi 1976 {published data only}</Title>
          <Reference>
            <Citation>Yagi G. 
A double‐blind controlled study on the usefulness of carpipramine‐chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. 
Rinsho Hyoka (Clinical Evaluation) 1976;4(3):351‐403.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Zhong 2001 {published data only}</Title>
          <Reference>
            <Citation>Zhong C, 
Guozhang J, 
Duochen W. 
A double‐blind comparison trial of 1‐stepholidine and perphenazine in treatment of schizophrenia. 
7th World Congress of Biological Psychiatry, Berlin, Germany. Suppl 1 2001; Vol. 2. 
[ZHONG: 2001]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Zhu 2009 {published data only}</Title>
          <Reference>
            <Citation>Zhu S, 
Liu Y, 
Sun S, 
Wang L. 
Psychological care on cognitive function in patients with chronic schizophrenia, the impact of (Google Translate) [心理护理对慢性精神分裂症患者认知功能的影响]. 
China Practical Medicine (中国实用医药) 2009; Vol. 4, issue 22:190‐2. 
[朱玉星,: 2009]
</Citation>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>References to studies awaiting assessment</Title>
        <ReferenceList>
          <Title>Casey 1960 {published data only}</Title>
          <Reference>
            <Citation>Casey JF, 
Lasky JJ, 
Klett CJ, 
Hollister LE. 
Treatment of schizophrenic reactions with phenothiazine derivates. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine and phenobarbital. 
American Journal of Psychiatry 1960;117:97‐105.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13808146</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Covell 2004 {published data only}</Title>
          <Reference>
            <Citation>Covell NH, 
Weissman EM, 
Essock SM. 
Weight gain with clozapine compared to first generation antipsychotic medications. 
Schizophrenia bulletin 2004; Vol. 30, issue 2:229‐40. 
[COVELL: 2004]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">15279042</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Ferziger 2010 {published data only}</Title>
          <Reference>
            <Citation>Ferziger R, 
Alphs L, 
Turner N, 
Mao L, 
Rodriguez S, 
Dixon L, 
et al. 
A multicenter effectiveness study of paliperidone palmitate vs oral antipsychotic drugs for people with schizophrenia recently released from jail: Study rationale and methodology. 
Neuropsychopharmacology 2010; Vol. 35:S101‐S2. 
[FERZIGER: 2010 a]
</Citation>
          </Reference>
          <Reference>
            <Citation>Ferziger R, 
Alphs L, 
Turner N, 
Mao L, 
Rodriguez S, 
Dixon L, 
et al. 
A multicenter effectiveness study of paliperidone palmitate vs oral antipsychotic drugs for people with schizophrenia recently released from jail: Study rationale and methodology. 
Proceedings of the 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida 2010. 
[FERZIGER: 2010]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Freedman 1961 {published data only}</Title>
          <Reference>
            <Citation>Freedman DX, 
Jong de J. 
Thresholds for drug‐induced akathisia. 
Journal of American Psychiatry 1961;117:930‐1.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13701605</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Freyhan 1959 {published data only}</Title>
          <Reference>
            <Citation>Freyhan FA. 
Therapeutic implications of differential effects of new phenothiazine compounds. 
American Journal of Psychiatry 1959;116:577‐85.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13617475</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Goldstein 1969 {published data only}</Title>
          <Reference>
            <Citation>Goldstein BJ, 
Brauzer B, 
Clyde DJ, 
Caldwell JM. 
The differential prediction of response to two anti‐psychotic drugs. 
Psychosomatics 1969;10(3):193‐7.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4897844</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hollister 1967 {published data only}</Title>
          <Reference>
            <Citation>Hollister LE, 
Overall JE, 
Bennett JL, 
Kimbell I, 
Shelton J. 
Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients. 
Clinical Pharmacology and Therapeutics 1967;8(2):249‐55.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">5336562</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kellam 1971 {published data only}</Title>
          <Reference>
            <Citation>Kellam AMP, 
Jones KS. 
A double‐blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy. 
Acta Psychiatrica Scandinavica 1971;47(2):174‐85.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4947996</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Mahmoud 2004 {published data only}</Title>
          <Reference>
            <Citation>Mahmoud RA, 
Engelhart LM, 
Janagap CC, 
Oster G, 
Ollendorf D. 
Risperidone versus conventional antipsychotic drugs for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. 
Clinical drug investigation 2004; Vol. 24, issue 5:275‐86. 
[MAHMOUD: 2004 a]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17503889</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>NCT 2011 {published data only}</Title>
          <Reference>
            <Citation>NCT. 
Decision aid to facilitate shared decision making during treatment in schizophrenia. 
http://ClinicalTrials.gov/show/NCT01420575 2011. 
[NCT01420575]
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Povlsen 1987 {published data only}</Title>
          <Reference>
            <Citation>Povlsen UJ, 
Noring U, 
Meidahl B, 
Korsgaard S, 
Waehrens J, 
Gerlach J. 
The effects of neuroleptics on tardive dyskinesias. A video‐controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden [Neuroleptikas virkning pa tardive dyskinesier. En videokontrolleret, randomiseret undersogelse med klorprotixen, perfenazin, haloperidol og haloperidol+biperiden]. 
Ugeskrift for Laeger 1987;149(25):1682‐5.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3299955</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Schulsinger 1958 {published data only}</Title>
          <Reference>
            <Citation>Schulsinger F, 
Jensen R. 
Trilafon (perphenazine) and largactil (chlorpromazine) in chronic schizophrenia. A comparison [Trilafon (perfenazin) og largactil (klorpromazin) hos kronisk sindssyge. En sammenligning]. 
Ugeskrift for Laeger 1958;120(12):366‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">13557071</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Szafranski 1999 {published data only}</Title>
          <Reference>
            <Citation>Szafranski T, 
Jarema M, 
Olajossy M, 
Chrzanowski W, 
Araszkiewicz A, 
Landowski J, 
et al. 
Subjective experiences of schizophrenic patients on atypical antipsychotic olanzapine and typical antipsychotic perphenazine. 
Journal of the European College of Neuropsychopharmacology 1999;9:273.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Vinar 1968 {published data only}</Title>
          <Reference>
            <Citation>Vinar O. 
Differences in therapeutic effects of phenothiazine drugs. 
Agressolgie 1968;9(2):315‐7.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4877493</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>Additional references</Title>
        <ReferenceList>
          <Title>Altman 1996</Title>
          <Reference>
            <Citation>Altman DG, 
Bland JM. 
Detecting skewness from summary information. 
BMJ 1996;313:1200.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2352469</ArticleId>
              <ArticleId IdType="pubmed">8916759</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Begg 1996</Title>
          <Reference>
            <Citation>Begg C, 
Cho M, 
Eastwood S, 
Horton R, 
Moher D, 
Ollon I, 
et al. 
Improving the quality of reporting of randomized controlled trials. The CONSORT statement [comment]. 
JAMA 1996;276:637‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">8773637</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Benkert 1996</Title>
          <Reference>
            <Citation>Benkert O, 
Hippius H. 
Psychiatrische Pharmakotherapie. 6th Edition. Berlin: Springer Verlag, 1996.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bland 1997</Title>
          <Reference>
            <Citation>Bland JM, 
Kerry SM. 
Trials in clusters. 
BMJ 1997;315:600.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2127388</ArticleId>
              <ArticleId IdType="pubmed">9302962</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bleuler 1908</Title>
          <Reference>
            <Citation>Bleuler E. 
[The prognosis of dementia praecox ‐ schizophrenia group ‐ Google translate] [Die Prognose der Dementia praecox ‐ Schizophreniegruppe]. 
Allgemeine Zeitschrift für Psychiatrie 1908;65:436‐64.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>BNF 2012</Title>
          <Reference>
            <Citation>BMJ Group and Pharmaceautical Press. 
British National Formulary No. 63. Antipsychotic drugs. 
BNF 2012.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Boissel 1999</Title>
          <Reference>
            <Citation>Boissel JP, 
Cucherat M, 
Li W, 
Chatellier G, 
Gueyffier F, 
Buyse M, 
et al. 
The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. 
Therapie 1999;54(4):405‐11. 
[PUBMED: 10667106]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">10667106</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bundesverband 2001</Title>
          <Reference>
            <Citation>Bundesverband der Pharmazeutischen Industrie (editors). 
No English title given [Fachinformation Decentan]. 
Fachinformation Decentan 2001:1‐4.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Cannon 1996</Title>
          <Reference>
            <Citation>Cannon M, 
Jones P. 
Schizophrenia. 
Journal of Neurology, Neurosurgery and Psychiatry 1996;61:604‐13.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC1073941</ArticleId>
              <ArticleId IdType="pubmed">8648325</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>CEA</Title>
          <Reference>
            <Citation>Cost‐Effectiveness Analysis Registry (CEA). 
https://research.tufts‐nemc.org/cear4/ accessed 11/09/13.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Clarke 2000</Title>
          <Reference>
            <Citation>Clarke M, 
Oxman AD. 
Cochrane Reviewers' Handbook. 
The Cochrane Library [database on disk and CDROM]. Oxford: Update Software, 2000.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>David 2005</Title>
          <Reference>
            <Citation>David A, 
Quraishi SN, 
Rathbone J. 
Depot perphenazine decanoate and enanthate for schizophrenia. 
Cochrane Database of Systematic Reviews 2005, Issue 3. 
[DOI: 10.1002/14651858.CD001717.pub2]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1002/14651858.CD001717.pub2</ArticleId>
              <ArticleId IdType="pmc">PMC7025790</ArticleId>
              <ArticleId IdType="pubmed">16034865</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Davies 2007</Title>
          <Reference>
            <Citation>Davies LM, 
Lewis S, 
Jones PB, 
Barnes TR, 
Gaughran F, 
Hayhurst K, 
et al. 
Cost‐effectiveness of first‐ v. second‐generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. 
British Journal of Psychiatry 2007;191:14‐22.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17602120</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Deeks 2000</Title>
          <Reference>
            <Citation>Deeks J. 
Issues in the selection for meta‐analyses of binary data. 
Abstracts of the 8th International Cochrane Colloquium. Cape Town, South Africa: Cochrane Collaboration, 2000 Oct 25th‐29th.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Divine 1992</Title>
          <Reference>
            <Citation>Divine GW, 
Brown JT, 
Frazer LM. 
The unit of analysis error in studies about physicians' patient care behavior. 
Journal of General Internal Medicine 1992;7:623‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">1453246</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Donner 2002</Title>
          <Reference>
            <Citation>Donner A, 
Klar N. 
Issues in the meta‐analysis of cluster randomized trials. 
Statistics in Medicine 2002;21:2971‐80.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">12325113</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Egger 1997</Title>
          <Reference>
            <Citation>Egger M, 
Smith GD, 
Schneider M, 
Minder C. 
Bias in meta‐analysis detected by a simple, graphical test. 
BMJ 1997;315:629‐34.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2127453</ArticleId>
              <ArticleId IdType="pubmed">9310563</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Elbourne 2002</Title>
          <Reference>
            <Citation>Elbourne D, 
Altman DG, 
Higgins JPT, 
Curtina F, 
Worthingtond HV, 
Vaile A. 
Meta‐analyses involving cross‐over trials: methodological issues. 
International Journal of Epidemiology 2002;31(1):140‐9.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">11914310</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Furukawa 2006</Title>
          <Reference>
            <Citation>Furukawa TA, 
Barbui C, 
Cipriani A, 
Brambilla P, 
Watanabe N. 
Imputing missing standard deviations in meta‐analyses can provide accurate results. 
Journal of Clinical Epidemiology 2006;59(7):7‐10.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">16360555</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Gulliford 1999</Title>
          <Reference>
            <Citation>Gulliford MC, 
Ukoumunne OC, 
Chinn S. 
Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. 
American Journal of Epidemiology 1999;149:876‐83.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">10221325</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Guy 1976</Title>
          <Reference>
            <Citation>Guy W. 
ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health. DHEW Publication NO (ADM), 1976:124‐585.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Higgins 2003</Title>
          <Reference>
            <Citation>Higgins JPT, 
Thompson SG, 
Deeks JJ, 
Altman DG. 
Measuring inconsistency in meta‐analyses. 
BMJ 2003;327:557‐60.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC192859</ArticleId>
              <ArticleId IdType="pubmed">12958120</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Higgins 2011</Title>
          <Reference>
            <Citation>Higgins JPT, 
Green S (editors). 
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. 
Available from www.cochrane‐handbook.org.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hutton 2009</Title>
          <Reference>
            <Citation>Hutton JL. 
Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. 
British Journal of Haematology 2009;146(1):27‐30.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">19438480</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>ICH E3 1995</Title>
          <Reference>
            <Citation>ICH Expert Working Group. 
ICH harmonised tripartite guideline: structure and content of clinical study reports. 
International conference on harmonisation of technical requirements for registration of pharmaceuticals for huma use 30 November 1995.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Jadad 1996</Title>
          <Reference>
            <Citation>Jadad AR, 
Moore RA, 
Carroll D, 
Jenkinson C, 
Reynolds DJM, 
Gavaghan DJ, 
et al. 
Assessing the quality of reports of randomized clinical trials: is blinding necessary?. 
Controlled Clinical Trials. Vol. 17, New York: Elsevier, 1996:1‐12.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">8721797</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kay 1986</Title>
          <Reference>
            <Citation>Kay SR, 
Opler LA, 
Fiszbein A. 
Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Kay 1987</Title>
          <Reference>
            <Citation>Kay SR, 
Fiszbein A, 
Opler LA. 
The positive and negative syndrome scale (PANSS) for schizophrenia. 
Schizophrenia Bulletin 1987;13:261‐76.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">3616518</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Leucht 2005</Title>
          <Reference>
            <Citation>Leucht S, 
Kane JM, 
Kissling W, 
Hamann J, 
Etschel E, 
Engel RR. 
What does the PANSS mean?. 
Schizophrenia Research 2005;79(2‐3):231‐8. 
[PUBMED: 15982856]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">15982856</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Leucht 2005a</Title>
          <Reference>
            <Citation>Leucht S, 
Kane JM, 
Kissling W, 
Hamann J, 
Etschel E, 
Engel R. 
Clinical implications of brief psychiatric rating scale scores. 
British Journal of Psychiatry 2005;187:366‐71. 
[PUBMED: 16199797]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">16199797</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Leucht 2007</Title>
          <Reference>
            <Citation>Leucht S, 
Engel RR, 
Bauml J, 
Davis JM. 
Is the superior efficacy of new generation antipsychotic drugs an artifact of LOCF?. 
Schizophrenia Bulletin 2007;33(1):183‐91. 
[PUBMED: 16905632]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC2632292</ArticleId>
              <ArticleId IdType="pubmed">16905632</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Lowe 1973</Title>
          <Reference>
            <Citation>Lowe GR. 
The phenomenology of hallucinations as an aid to differential diagnosis. 
British Journal of Psychiatry 1973;123:621‐33.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">4772302</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Mangalore 2007</Title>
          <Reference>
            <Citation>Mangalore R, 
Knapp M. 
Cost of schizophrenia in England. 
Journal of Mental Health Policy and Economics 2007;10(1):23‐41.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">17417045</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Marshall 2000</Title>
          <Reference>
            <Citation>Marshall M, 
Lockwood A, 
Bradley C, 
Adams C, 
Joy C, 
Fenton M. 
Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. 
British Journal of Psychiatry 2000;176:249‐52.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">10755072</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Moher 2001</Title>
          <Reference>
            <Citation>Moher D, 
Schultz KF, 
Altman DG. 
The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials. 
Lancet 2001;357:1191‐4.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">11323066</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>NICE 2010</Title>
          <Reference>
            <Citation>National Collaborating Centre for Mental Health. 
Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). 
National Clinical Guideline Number 82 2010.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Overall 1962</Title>
          <Reference>
            <Citation>Overall JE, 
Gorham DR. 
The Brief Psychiatric Rating Scale. 
Psychological Reports 1962;10:799‐812.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Parfitt 1999</Title>
          <Reference>
            <Citation>Parfitt K (editor). 
Martindale. The Complete Drug Reference. 2nd Edition. London: Pharmaceutical Press, 1999.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Rosenheck 2009</Title>
          <Reference>
            <Citation>Rosenheck RA, 
Davis VG, 
Davis SM, 
Stroup S, 
McEvoy J, 
Swartz M, 
et al. 
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. 
Schizophrenia Research 2009;113(1):12‐8.
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pmc">PMC6474782</ArticleId>
              <ArticleId IdType="pubmed">19545976</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Schünemann 2008</Title>
          <Reference>
            <Citation>Schünemann HJ, 
Oxman AD, 
Vist GE, 
Higgins JPT, 
Deeks JJ, 
Glasziou P, 
et al. 
Chapter 12: Interpreting results and drawing conclusions. 
In: Higgins JPT, 
Green S editor(s). 
Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Ukoumunne 1999</Title>
          <Reference>
            <Citation>Ukoumunne OC, 
Gulliford MC, 
Chinn S, 
Sterne JAC, 
Burney PGJ. 
Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. 
Health Technology Assessment 1999;3(5):iii‐92. 
[MEDLINE: ]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="pubmed">10982317</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Wing 1961</Title>
          <Reference>
            <Citation>Wing J. 
A simple and reliable subclassification of chronic schizophrenia. 
British Journal of Psychiatry 1967;107:862‐75. 
[DOI: 10.1192/bjp.107.450.862]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1192/bjp.107.450.862</ArticleId>
              <ArticleId IdType="pubmed">14007482</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Xia 2009</Title>
          <Reference>
            <Citation>Xia J, 
Adams CE, 
Bhagat N, 
Bhagat V, 
Bhoopathi P, 
El‐Sayeh H, 
et al. 
Loss to outcomes stakeholder survey: the LOSS study. 
Psychiatric Bulletin 2009;33(7):254‐7.
</Citation>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>References to other published versions of this review</Title>
        <ReferenceList>
          <Title>Hartune 2005</Title>
          <Reference>
            <Citation>Hartung B, 
Wada M, 
Laux G, 
Leucht S. 
Perphenazine for schizophrenia. 
Cochrane Database of Systematic Reviews 2005, Issue 1. 
[DOI: 10.1002/14651858.CD003443.pub2]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1002/14651858.CD003443.pub2</ArticleId>
              <ArticleId IdType="pubmed">15674907</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
